Here, we demonstrate that EGFR-targeting small-molecule inhibitors have efficacy in EGFR-amplified oesophageal squamous cell carcinoma (ESCC), but may become quickly ineffective. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.